Gilead's hepatitis C drugs largely cost-effective in U.S.: study

March 16, 2015 9:04 PM

14 0

(Reuters Health) - New hepatitis C drugs that shorten treatment times are largely cost-effective despite their hefty U.S. price tags, according to two new analyses.

The widespread use of a combination of drugs that include Gilead Sciences Inc's Sovaldi, known generically as sofosbuvir, will nonetheless be a significant cost for the U.S. healthcare system, researchers wrote.

Read more

To category page